Tegrigen Therapeutics

Tegrigen Therapeutics (also known as Alpha-5 Integrin, LLC) is a pre-clinical stage biotechnology company specializing in the development of novel therapeutics targeting specific integrins. The company's research focuses on developing pure orthosteric antagonists and monoclonal antibodies to address life-threatening conditions such as inflammation, fibrosis, thrombosis, autoimmunity, neurodegeneration, and cancer. Its lead programs include PAS-003, a monoclonal antibody targeting alpha-5 beta-1 integrin for the treatment of amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and mAb107, a monoclonal antibody targeting CD11b to prevent ischemia-reperfusion injury and kidney transplant rejection. Tegrigen was co-founded by prominent scientists, including Dr. Donald Landry, Dr. Bradley Pentelute, and Dr. M. Amin Arnaout. In June 2022, the company was acquired by Pasithea Therapeutics Corp. to advance its integrin-targeting pipeline.